On a preclinical level, TN14003 and AMD3100 (Plerixafor), two anti-CXCR4 inhibitors, have been tested in patient-derived xenografts (PDX) of breast cancer showing antitumor activity in the HER2 subtype (94). This evidence concerns the gene CXCR4 and breast carcinoma.